OncoMatch/Clinical Trials/NCT04464759
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Is NCT04464759 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Nivolumab and Hydroxychloroquine for melanoma.
Treatment: Nivolumab · Hydroxychloroquine · Ipilimumab — This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: PD-L1 (CD274) any tested
any programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
Exception: Phase 2 Cohort 2a: prior immunotherapy required; Phase 2 Cohort 2b: anti-PD-1 Ab-naïve only; Phase 1b: anti-PD-1 refractory required
Phase 2 nivolumab + HCQ Cohort B: No prior immunotherapy is permitted
Cannot have received: active immunotherapy, chemotherapy, or investigational anticancer therapy
Exception: must be discontinued >= 4 weeks prior to study entry (oral targeted therapy >= 2 weeks)
Must have discontinued active immunotherapy, chemotherapy, or investigational anticancer therapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Abramson Cancer Center at University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify